The Valley Desk

ArticleFuture oncology (London, England)Published

Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Liposarcoma; Doxorubicin; Tumor Suppressor Protein p53; Proto-Oncogene Proteins c-mdm2; Multicenter Studies as Topic; Clinical Trials, Phase III as Topic; doxorubicin; Dedifferentiated Liposarcoma; Phase Ii/iii Trial; Bi 907828; Mdm2–p53 Antagonist
PubMed ID
36987836
Added to directory
Source checked

Report a correction or request removal